Skip to main content
. 2021 Nov 13;22(22):12282. doi: 10.3390/ijms222212282

Figure 14.

Figure 14

cGMP level (A) and GluN2B subunit-containing NMDA receptor expression (B) in the prefrontal cortex (PFC) and hippocampus (Hipp) after chronic (14 days) administration of MK-801 (0.3 mg/kg) or scopolamine (1 mg/kg). (C) Representative Western blots. Data are presented as means ± SEM. * p < 0.05; ** p < 0.01 vs. control.